 | Up a level |
Lee, Victor Ho-Fun and Adham, Marlinda and Ben Kridis, Wala and Bossi, Paolo and Chen, Ming-Yuan and Chitapanarux, Imjai and Gregoire, Vincent and Hao, Sheng Po and Ho, Cheryl and Ho, Gwo Fuang and Kannarunimit, Danita and Kwong, Dora Lai-Wan and Lam, Ka-On and Lam, Wai Kei Jacky and Le, Quynh-Thu and Lee, Anne Wing-Mui and Lee, Nancy Y. and Leung, To-Wai and Licitra, Lisa and Lim, Darren Wan-Teck and Lin, Jin-Ching and Loh, Kwok Seng and Lou, Pei-Jen and Machiels, Jean-Pascal and Mai, Hai-Qiang and Mesia, Ricard and Ng, Wai-Tong and Ngan, Roger Kai-Cheong and Tay, Joshua K. and Tsang, Raymond King-Yin and Tong, Chi-Chung and Wang, Hung-Ming and Wee, Joseph T. (2022) International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: Lessons from the COVID-19 pandemic. Lancet Oncology, 23 (12). E544-E551. ISSN 1470-2045,
McLeod, Megan and Torode, Julie and Leung, Kari and Bhoo-Pathy, Nirmala and Booth, Christopher and Chakowa, Jade and Gralow, Julie and Ilbawi, Andre and Jassem, Jacek and Parkes, Jeannette and Mallafre-Larrosa, Merixtell and Mutebi, Miriam and Pramesh, C. S. and Sengar, Manju and Tsunoda, Audrey and Unger-Saldana, Karla and Vanderpuye, Verna and Yusuf, Aasim and Sullivan, Richard and Aggarwal, Ajay (2024) Quality indicators for evaluating cancer care in low-income and middle-income country settings: a multinational modified Delphi study. Lancet Oncology, 25 (2). e63-e72. ISSN 1470-2045, DOI https://doi.org/10.1016/S1470-2045(23)00568-5.
Wu, Yi-Long and Guarneri, Valentina and Voon, Pei Jye and Lim, Boon Khaw and Yang, Jin-Ji and Wislez, Marie and Huang, Cheng and Liam, Chong Kin and Mazieres, Julien and Tho, Lye Mun and Hayashi, Hidetoshi and Nhung, Nguyen Viet and Chia, Puey Ling and de Marinis, Filippo and Raskin, Jo and Zhou, Qinghua and Finocchiaro, Giovanna and Le, Anh Tuan and Wang, Jialei and Dooms, Christophe and Kato, Terufumi and Nadal, Ernest and Hin, How Soon and Smit, Egbert F. and Wermke, Martin and Tan, Daniel and Morise, Masahiro and O'Brate, Aurora and Adrian, Svenja and Pfeiffer, Boris M. and Stroh, Christopher and Juraeva, Dilafruz and Strotmann, Rainer and Goteti, Kosalaram and Berghoff, Karin and Ellers-Lenz, Barbara and Karachaliou, Niki and Le, Xiuning and Kim, Tae Min and INSIGHT investigators, - (2024) Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. Lancet Oncology, 25 (8). pp. 989-1002. ISSN 1470-2045, DOI https://doi.org/10.1016/S1470-2045(24)00270-5.
